1. Obicetrapib reduced LDL cholesterol by 29.9% in high-risk cardiovascular patients receiving intensive lipid-lowering therapy.
2. The trial enrolled 2,530 adult patients with cardiovascular disease or familial hypercholesterolemia.
3. The LDL-lowering effect of obicetrapib slightly diminished over 12 months.
4. Adverse events occurred in 59.7% of obicetrapib-treated patients.
5. No significant safety concerns were identified during the study.

Source: The New England Journal of Medicine